UY35412A - Formulaciones de fviii recombinante - Google Patents

Formulaciones de fviii recombinante

Info

Publication number
UY35412A
UY35412A UY0001035412A UY35412A UY35412A UY 35412 A UY35412 A UY 35412A UY 0001035412 A UY0001035412 A UY 0001035412A UY 35412 A UY35412 A UY 35412A UY 35412 A UY35412 A UY 35412A
Authority
UY
Uruguay
Prior art keywords
rfviii
formulations
bdd
mutant
pegylated
Prior art date
Application number
UY0001035412A
Other languages
English (en)
Spanish (es)
Inventor
Ma Xinghang
Wang Deqian
Tsvetkova Nelly
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of UY35412A publication Critical patent/UY35412A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UY0001035412A 2013-03-15 2014-03-13 Formulaciones de fviii recombinante UY35412A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361799495P 2013-03-15 2013-03-15
US201361869191P 2013-08-23 2013-08-23

Publications (1)

Publication Number Publication Date
UY35412A true UY35412A (es) 2014-10-31

Family

ID=51580768

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035412A UY35412A (es) 2013-03-15 2014-03-13 Formulaciones de fviii recombinante

Country Status (17)

Country Link
US (1) US20160030524A1 (cg-RX-API-DMAC10.html)
EP (1) EP2970430A4 (cg-RX-API-DMAC10.html)
JP (1) JP2016518321A (cg-RX-API-DMAC10.html)
KR (1) KR20150132449A (cg-RX-API-DMAC10.html)
CN (1) CN105209487A (cg-RX-API-DMAC10.html)
AU (1) AU2014237111B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015022730A2 (cg-RX-API-DMAC10.html)
CA (1) CA2905739A1 (cg-RX-API-DMAC10.html)
HK (1) HK1213273A1 (cg-RX-API-DMAC10.html)
MX (1) MX2015012905A (cg-RX-API-DMAC10.html)
PE (1) PE20160121A1 (cg-RX-API-DMAC10.html)
RU (1) RU2015144076A (cg-RX-API-DMAC10.html)
SG (2) SG10201803999UA (cg-RX-API-DMAC10.html)
TW (1) TW201521761A (cg-RX-API-DMAC10.html)
UY (1) UY35412A (cg-RX-API-DMAC10.html)
WO (1) WO2014150477A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201507684B (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016115561A1 (en) * 2015-01-18 2016-07-21 Biogen Ma Inc. Formulations and screening of biological therapeutic agents
CN108884145B (zh) 2015-11-13 2023-08-22 武田药品工业株式会社 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
US12091675B2 (en) 2018-07-16 2024-09-17 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
WO2021032646A1 (en) * 2019-08-16 2021-02-25 Octapharma Ag Stabilizing buffer for factor viii and vwf

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
CN1339170A (zh) * 1999-02-01 2002-03-06 日本电气硝子株式会社 阴极射线管及其制造方法
EP1820516B1 (en) * 1999-02-22 2013-07-24 University of Connecticut Novel albumin-free factor VIII formulations
EP1421539B1 (en) * 2001-06-14 2009-10-28 The Scripps Research Institute Stabilized factor viii with engineered disulfide bonds
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
DK2371856T3 (en) * 2004-11-12 2022-08-08 Bayer Healthcare Llc Site-directed modifikation af FVIII
WO2007126808A1 (en) * 2006-03-31 2007-11-08 Baxter International Inc Pegylated factor viii
EP2385825B1 (en) * 2008-11-07 2018-10-10 University of Connecticut Factor viii formulations
CA2748662A1 (en) * 2009-01-19 2010-07-22 Bayer Healthcare Llc Protein conjugate having an endopeptidase-cleavable bioprotective moiety

Also Published As

Publication number Publication date
EP2970430A1 (en) 2016-01-20
ZA201507684B (en) 2017-06-28
SG11201507618YA (en) 2015-10-29
CA2905739A1 (en) 2014-09-25
BR112015022730A2 (pt) 2017-10-31
SG10201803999UA (en) 2018-06-28
CN105209487A (zh) 2015-12-30
PE20160121A1 (es) 2016-03-03
HK1213273A1 (zh) 2016-06-30
WO2014150477A1 (en) 2014-09-25
KR20150132449A (ko) 2015-11-25
US20160030524A1 (en) 2016-02-04
RU2015144076A (ru) 2017-04-24
AU2014237111A1 (en) 2015-10-08
MX2015012905A (es) 2016-06-16
AU2014237111B2 (en) 2018-06-21
EP2970430A4 (en) 2017-01-11
TW201521761A (zh) 2015-06-16
JP2016518321A (ja) 2016-06-23

Similar Documents

Publication Publication Date Title
CO2019005966A2 (es) Esteroides y conjugados de proteínas de los mismos
CY1122101T1 (el) Τροποποιημενα πολυπεπτιδια ρελαξινης και χρησεις αυτων
MX386802B (es) Vectores del factor viii del virus adeno-asociado.
MX382518B (es) Antigenos de citomegalovirus y su uso.
SG10201809457YA (en) Insulin receptor partial agonists
MX2016001094A (es) Nanoemulsion de aminosilicona.
UY33856A (es) ?gen y variaciones asociadas con el fenotipo bm1, marcadores moleculares y su uso?.
MX376324B (es) Proteinas de union a desmogelina 2 (dsg2) y usos de los mismos.
UY34740A (es) Atomizador con agentes codificadores
UY34200A (es) 3-(fluorovinil)pirazoles y su uso
IL283043A (en) Methods for shrinking pituitary tumors
EA201591832A1 (ru) Коэкспрессия фактора viii и фактора фон виллебранда
EA201691429A1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
MX377022B (es) Composiciones de lágrimas artificiales.
EP3535770A4 (en) SWITCH WITH LIGHTING STRUCTURE AND DISPLAY
EP3723771A4 (en) RECOMBINANT ADENOVIRUS AND USES THEREOF
HUE050362T2 (hu) Javított rekombináns fehérje expresszió hibrid CHEF1 promótert alkalmazva
UY34590A (es) Fenilimidazopirazoles sustituidos y su uso
EP2948469A4 (en) STABILIZED HEPATITIS B CORE POLYPEPTIDE
MX2015012905A (es) Formulaciones de factor viii recombinantes.
UY4239Q (es) Silla con respaldo en forma de t
AR095431A1 (es) Formulaciones de fviii recombinante
CO7051011A2 (es) Anticuerpos recombinantes con especificidad dual por gangliósidos y su uso
UA86172U (en) Suppository
EA201891475A1 (ru) Система механической фиксации панелей пола

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211112